| scholarly article | Q13442814 |
| P356 | DOI | 10.1212/WNL.0000000000000402 |
| P698 | PubMed publication ID | 24727314 |
| P50 | author | Martin Bendszus | Q40395521 |
| Benedikt Wiestler | Q92123609 | ||
| Heinz-Peter Schlemmer | Q101385190 | ||
| Wolfgang Wick | Q2591750 | ||
| P2093 | author name string | Markus Hutterer | |
| Alexander Radbruch | |||
| Günther Stockhammer | |||
| Martha Nowosielski | |||
| Georg Goebel | |||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiogenesis inhibitor | Q574834 |
| P304 | page(s) | 1684-1692 | |
| P577 | publication date | 2014-04-11 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. | |
| P478 | volume | 82 |
| Q47105371 | "Paradoxical" findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab |
| Q36082501 | A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma |
| Q31130812 | A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma |
| Q30983681 | Advanced MR Imaging in Neuro-oncology |
| Q36374577 | An Update on the Approach to the Imaging of Brain Tumors |
| Q38635290 | Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? |
| Q39225820 | Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response |
| Q39313983 | Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications |
| Q46343256 | Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab |
| Q36218548 | Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment |
| Q37245796 | Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma |
| Q57181734 | Comparative Histologic and Molecular Analysis of 2 Recurrent Lesions Showing Different Magnetic Resonance Imaging Responses After Bevacizumab Treatment: Report of a Case of Anaplastic Astrocytoma |
| Q35891430 | Computational Trials: Unraveling Motility Phenotypes, Progression Patterns, and Treatment Options for Glioblastoma Multiforme |
| Q36367172 | Current Clinical Brain Tumor Imaging |
| Q26853308 | Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients |
| Q36618235 | Current status and future directions of anti-angiogenic therapy for gliomas |
| Q99631295 | Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies |
| Q41616011 | Disease progression patterns of bevacizumab responders with recurrent malignant gliomas. |
| Q31043028 | Downfield-NOE-suppressed amide-CEST-MRI at 7 Tesla provides a unique contrast in human glioblastoma |
| Q55456668 | Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine. |
| Q41547838 | Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study |
| Q57739391 | Edge Contrast of the FLAIR Hyperintense Region Predicts Survival in Patients with High-Grade Gliomas following Treatment with Bevacizumab |
| Q34703888 | Effects of anti-angiogenesis on glioblastoma growth and migration: model to clinical predictions. |
| Q58568066 | Evaluating cellularity and structural connectivity on whole brain slides using a custom-made digital pathology pipeline |
| Q90618650 | Glioblastoma Treatment Modalities besides Surgery |
| Q45813730 | Highlights from the Literature |
| Q48292017 | How treatment monitoring is influencing treatment decisions in glioblastomas |
| Q50055297 | Hypoxia Activated Evofosfamide for Treatment of Recurrent Bevacizumab-Refractory Glioblastoma: A phase I surgical study |
| Q54973707 | Imaging in neuro-oncology. |
| Q43006239 | Is a picture really worth a 1000 words? |
| Q39268920 | Key rates for the grades and transformation ability of glioma: model simulations and clinical cases |
| Q40497804 | Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response |
| Q48112689 | Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival |
| Q33586021 | Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials |
| Q63386974 | Neuroimaging classification of progression patterns in glioblastoma: a systematic review |
| Q38268897 | Pharmacologic therapies for malignant glioma: a guide for clinicians. |
| Q35675340 | Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma |
| Q40886583 | Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas |
| Q88201920 | Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686 |
| Q30860126 | Pros and cons of current brain tumor imaging |
| Q30938479 | Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI |
| Q38681619 | Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients |
| Q46410971 | Radiologic progression of glioblastoma under therapy - an exploratory analysis of AVAglio |
| Q35815295 | Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma |
| Q34331320 | Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). |
| Q45945655 | Response Assessment in Neuro-Oncology Clinical Trials. |
| Q88852234 | Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma |
| Q53738336 | Response assessment in high-grade glioma: tumor volume as endpoint. |
| Q96165810 | Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group |
| Q52655328 | Retrospective Analysis of Radiological Recurrence Patterns in Glioblastoma, Their Prognostic Value And Association to Postoperative Infarct Volume. |
| Q34359710 | Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab |
| Q36238522 | Single Cell Mathematical Model Successfully Replicates Key Features of GBM: Go-Or-Grow Is Not Necessary |
| Q56333957 | The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space |
| Q48175331 | The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET). |
| Q88886485 | Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial |
| Q53491303 | [Towards more precision in the therapy of brain tumors. Possibilities and limits of MRI]. |
Search more.